"Multiple Sclerosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
Descriptor ID |
D009103
|
MeSH Number(s) |
C10.114.375.500 C10.314.350.500 C20.111.258.250.500
|
Concept/Terms |
Multiple Sclerosis- Multiple Sclerosis
- Sclerosis, Multiple
- Sclerosis, Disseminated
- Disseminated Sclerosis
- MS (Multiple Sclerosis)
|
Below are MeSH descriptors whose meaning is more general than "Multiple Sclerosis".
Below are MeSH descriptors whose meaning is more specific than "Multiple Sclerosis".
This graph shows the total number of publications written about "Multiple Sclerosis" by people in this website by year, and whether "Multiple Sclerosis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 4 | 0 | 4 |
1995 | 4 | 1 | 5 |
1996 | 9 | 0 | 9 |
1997 | 2 | 0 | 2 |
1998 | 7 | 2 | 9 |
1999 | 3 | 0 | 3 |
2000 | 2 | 0 | 2 |
2002 | 4 | 0 | 4 |
2003 | 2 | 0 | 2 |
2004 | 3 | 0 | 3 |
2005 | 3 | 0 | 3 |
2006 | 2 | 0 | 2 |
2007 | 4 | 0 | 4 |
2008 | 2 | 1 | 3 |
2009 | 4 | 0 | 4 |
2010 | 4 | 2 | 6 |
2011 | 6 | 1 | 7 |
2012 | 7 | 1 | 8 |
2013 | 7 | 0 | 7 |
2014 | 4 | 0 | 4 |
2015 | 2 | 0 | 2 |
2016 | 2 | 0 | 2 |
2017 | 4 | 1 | 5 |
2018 | 5 | 0 | 5 |
2019 | 4 | 0 | 4 |
2020 | 4 | 1 | 5 |
2021 | 7 | 0 | 7 |
2022 | 6 | 0 | 6 |
2023 | 6 | 0 | 6 |
2024 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Multiple Sclerosis" by people in Profiles.
-
Polysomnography parameters in a large cohort of people with multiple sclerosis. Sleep Med. 2024 Sep; 121:236-240.
-
Alternative Splicing of RNA Is Excessive in Multiple Sclerosis and Not Linked to Gene Expression Levels: Dysregulation Is Corrected by IFN-ß. J Interferon Cytokine Res. 2024 Aug; 44(8):355-371.
-
Novel biomarkers and interferon signature in secondary progressive multiple sclerosis. J Neuroimmunol. 2024 04 15; 389:578328.
-
Genetic deletion of c-Jun amino-terminal kinase 3 (JNK3) modestly increases disease severity in a mouse model of multiple sclerosis. J Neuroimmunol. 2023 09 15; 382:578152.
-
Demographics and baseline disease characteristics of Black and Hispanic patients with multiple sclerosis in the open-label, single-arm, multicenter, phase IV CHIMES trial. Mult Scler Relat Disord. 2023 Aug; 76:104794.
-
Understanding humoral immunity and multiple sclerosis severity in Black, and Latinx patients. Front Immunol. 2023; 14:1172993.
-
Clostridium epsilon toxin is excessive in multiple sclerosis and provokes multifocal lesions in mouse models. J Clin Invest. 2023 05 01; 133(9).
-
Prolonged Interferon-Stimulated Gene and Protein Signatures in Multiple Sclerosis Induced by PEGylated IFN-ß-1a Compared to Non-PEGylated IFN-ß-1a. J Interferon Cytokine Res. 2023 03; 43(3):108-120.
-
Effectiveness of ocrelizumab on clinical and MRI outcome measures in multiple sclerosis across black and white cohorts: A single-center retrospective study. Mult Scler Relat Disord. 2023 Mar; 71:104523.
-
Increased Percentage of CD8+CD28- Regulatory T Cells With Fingolimod Therapy in Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023 03; 10(2).